MBX Biosciences to Participate in March Investor Conferences

GlobeNewswireFeb 18 08:00 ET

Earnings Scheduled For February 13, 2025

BenzingaFeb 13 03:32 ET

Smaller Biotechs See New Mechanisms of Actions as Future of Obesity Treatments

Seeking AlphaFeb 10 12:34 ET

Stifel Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $40

Moomoo NewsFeb 10 08:31 ET · Ratings

Stifel Nicolaus Reaffirms Their Buy Rating on MBX Biosciences, Inc. (MBX)

TipRanksFeb 10 07:45 ET · Ratings

MBX Biosciences Director Makes Bold Stock Move

TipRanksFeb 5 21:08 ET

Insider Purchase: President & CEO of $MBX Buys 50,000 Shares

Quiver QuantitativeFeb 5 16:32 ET

Applied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

BenzingaJan 15 08:52 ET

Why Vision Marine Technologies Shares Are Trading Higher By 68%; Here Are 20 Stocks Moving Premarket

BenzingaJan 15 05:10 ET

MBX Biosciences Shares Are Trading Higher on Possible Continued Strength After the Company Announced Results From Its Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of MBX 1416 Yesterday.

BenzingaJan 8 08:26 ET

J.P. Morgan Maintains MBX Biosciences(MBX.US) With Buy Rating

Moomoo NewsJan 8 06:31 ET · Ratings

MBX Biosciences, Inc. (MBX) Receives a Buy From J.P. Morgan

TipRanksJan 8 06:28 ET

MBX Biosciences' Investigational Drug For Weight Loss Surgery-Related Low Blood Sugar Shows Encouraging Action

BenzingaJan 7 11:47 ET

Express News | Mbx Biosciences Inc - 1416 Generally Well-Tolerated With Favorable Safety Profile

ReutersJan 7 07:00 ET

12 Health Care Stocks Moving In Thursday's Pre-Market Session

BenzingaJan 2 16:05 ET

Earnings Scheduled For December 19, 2024

BenzingaDec 19, 2024 03:32 ET

MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswireDec 18, 2024 08:00 ET

MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published In The Journal Of Clinical Endocrinology And Metabolism

BenzingaDec 2, 2024 09:06 ET

MBX Biosciences Announces The Completion Of The Last Subject's Last Visit In Its Phase 1 Single And Multiple Ascending Dose Trial Of MBX 1416, The Company's Long-Acting Glucagon-Like Peptide 1 Receptor Antagonist In Development For The Treatment Of...

BenzingaNov 18, 2024 08:19 ET

Express News | Mbx Biosciences : Look Forward to Sharing Full-Topline Results of Mbx 1416 Program in Early January 2025

ReutersNov 18, 2024 08:03 ET